| atorvastatin vs placebo | No demonstrated result suggested recurrent angina by 26% (not demonstrated) suggested Non fatal stroke by 59% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Deaths or MI | 0.92 [0.73 1.16] | p=1.00 | 0 | 3086 | 1 | MIRACL, | | cardiovascular events at 1 month | 1.06 [0.79 1.41] | p=1.00 | 0 | 3086 | 1 | MIRACL, | | cardiovascular events at 4 months | 0.89 [0.71 1.12] | p=1.00 | 0 | 3086 | 1 | MIRACL, | | PTCA | 1.06 [0.83 1.34] | p=1.00 | 0 | 3086 | 1 | MIRACL, | | recurrent angina | 0.74 [0.56 0.97] | p=0.04 | 0 | 3086 | 1 | MIRACL, | | cardiovascular events | 0.92 [0.73 1.16] | p=1.00 | 0 | 3086 | 1 | MIRACL, | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | 0.50 [0.25 1.01] | p=1.00 | 0 | 3086 | 1 | MIRACL, | | cardiac death | 0.86 [0.58 1.25] | p=1.00 | 0 | 3086 | 1 | MIRACL, | | CABG | 0.97 [0.74 1.28] | p=1.00 | 0 | 3086 | 1 | MIRACL, | | Fatal MI | 0.95 [0.49 1.85] | p=1.00 | 0 | 3086 | 1 | MIRACL, | | Non fatal MI | 0.90 [0.68 1.19] | p=1.00 | 0 | 3086 | 1 | MIRACL, | | Revascularization | 1.02 [0.84 1.24] | p=1.00 | 0 | 3086 | 1 | MIRACL, | | All cause death | 0.95 [0.67 1.34] | p=1.00 | 0 | 3086 | 1 | MIRACL, | | Non fatal stroke | 0.41 [0.19 0.90] | p=0.04 | 0 | 3086 | 1 | MIRACL, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| atorvastatin vs pravastatin | No demonstrated result suggested cardiovascular events by 24% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Deaths or MI | no data | | cardiovascular events at 1 month | no data | | cardiovascular events at 4 months | no data | | PTCA | no data | | recurrent angina | no data | | cardiovascular events | 0.76 [0.66 0.88] | p=0.04 | 0 | 4152 | 1 | PROVE IT - TIMI 22, | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | cardiac death | no data | | CABG | no data | | Fatal MI | no data | | Non fatal MI | no data | | Revascularization | no data | | All cause death | 0.72 [0.50 1.03] | p=1.00 | 0 | 4152 | 1 | PROVE IT - TIMI 22, | | Non fatal stroke | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| atorvastatin vs usual care | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Deaths or MI | no data | | cardiovascular events at 1 month | 0.15 [0.01 2.93] | p=1.00 | 0 | 81 | 1 | Colivicchi, | | cardiovascular events at 4 months | 0.53 [0.17 1.64] | p=1.00 | 0 | 151 | 2 | Colivicchi,ESTABLISH, | | PTCA | no data | | recurrent angina | no data | | cardiovascular events | 0.53 [0.17 1.64] | p=1.00 | 0 | 151 | 2 | Colivicchi,ESTABLISH, | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | 0.62 [0.08 4.92] | p=1.00 | 0 | 151 | 2 | Colivicchi,ESTABLISH, | | cardiac death | 0.73 [0.14 3.89] | p=1.00 | 0 | 151 | 2 | Colivicchi,ESTABLISH, | | CABG | no data | | Fatal MI | 0.73 [0.14 3.89] | p=1.00 | 0 | 151 | 2 | Colivicchi,ESTABLISH, | | Non fatal MI | 0.48 [0.13 1.85] | p=1.00 | 0 | 151 | 2 | Colivicchi,ESTABLISH, | | Revascularization | 1.00 [0.34 2.93] | p=1.00 | 0 | 151 | 2 | Colivicchi,ESTABLISH, | | All cause death | 0.66 [0.16 2.68] | p=1.00 | 0 | 151 | 2 | Colivicchi,ESTABLISH, | | Non fatal stroke | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| atorvastatin vs placebo | Coronary event by 26% (fully demonstrated) MACE by 20% (fully demonstrated) suggested TIA by 26% (not demonstrated) suggested cardiovascular events by 16% (not demonstrated) suggested Cardiovascular death by 16% (not demonstrated) suggested stroke (fatal and non fatal) by 20% (not demonstrated) suggested stroke or TIA by 21% (not demonstrated) suggested Coronary death and non fatal MI by 35% (not demonstrated) suggested Non fatal MI by 40% (not demonstrated) suggested Fatal stroke by 46% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Amputation | 0.48 [0.01 24.09] | p=1.00 | 0 | 354 | 1 | Mohler III, | | Venous thromboembolism | no data | | TIA | 0.74 [0.59 0.91] | p=0.04 | 0 | 4731 | 1 | SPARCL, | | cardiovascular events | 0.84 [0.76 0.94] | p=0.04 | 0 | 11237 | 4 | CARDS,Deutsche Diabetes Dialyse Studie (4D),SPARCL,ASPEN, | | Cardiovascular death | 0.84 [0.72 0.98] | p=0.04 | 0 | 21896 | 6 | Mohler III,CARDS,ASCOT,Deutsche Diabetes Dialyse Studie (4D),SPARCL,ASPEN, | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | 0.80 [0.70 0.92] | p=0.04 | 0 | 20287 | 4 | CARDS,ASCOT,SPARCL,ASPEN, | | stroke or TIA | 0.79 [0.68 0.92] | p=0.04 | 0 | 4731 | 1 | SPARCL, | | Coronary event | 0.74 [0.66 0.83] | p=0.04 | 0 | 21542 | 5 | CARDS,ASCOT,Deutsche Diabetes Dialyse Studie (4D),SPARCL,ASPEN, | | Coronary death and non fatal MI | 0.65 [0.50 0.83] | p=0.04 | 0 | 10305 | 1 | ASCOT, | | Coronary death | 0.74 [0.40 1.37] | p=1.00 | 0 | 2841 | 1 | CARDS, | | cardiac death | no data | | MACE | 0.80 [0.71 0.89] | p=0.04 | 0 | 15556 | 3 | CARDS,ASCOT,ASPEN, | | Non vascular death | no data | | Fatal MI | no data | | Non fatal MI | 0.60 [0.36 1.00] | p=0.04 | 0 | 2841 | 1 | CARDS, | | Revascularization | 0.24 [0.02 2.65] | p=1.00 | 0 | 354 | 1 | Mohler III, | | All cause death | 0.92 [0.82 1.03] | p=1.00 | 0 | 19486 | 5 | Mohler III,CARDS,ASCOT,Deutsche Diabetes Dialyse Studie (4D),SPARCL, | | non cardiovascular death | 0.91 [0.76 1.09] | p=1.00 | 0 | 11560 | 2 | ASCOT,Deutsche Diabetes Dialyse Studie (4D), | | Fatal stroke | 0.54 [0.33 0.89] | p=0.04 | 0 | 7572 | 2 | CARDS,SPARCL, | | Non fatal stroke | 0.88 [0.74 1.06] | p=1.00 | 0 | 4731 | 1 | SPARCL, | | Haemmorhagic stroke | 0.99 [0.02 49.84] | p=1.00 | 0 | 2841 | 1 | CARDS, | | new-onset diabetes | 1.14 [0.89 1.46] | p=1.00 | 0 | 7773 | 1 | ASCOT, | | Death from cancer | 0.66 [0.37 1.17] | p=1.00 | 0 | 2841 | 1 | CARDS, | | Rhabdomyolysis | 1.92 [0.16 22.88] | p=1.00 | 0 | 13146 | 2 | CARDS,ASCOT, | | Myopathy | 0.99 [0.06 15.81] | p=1.00 | 0 | 2841 | 1 | CARDS, | | Cancer | no data | | Adverse events | 0.94 [0.50 1.77] | p=1.00 | 0 | 2841 | 1 | CARDS, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| atorvastatin vs usual care | No demonstrated result suggested Coronary event by 51% (not demonstrated) suggested cardiac death by 43% (not demonstrated) suggested All cause death by 43% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Venous thromboembolism | no data | | cardiovascular events | no data | | Cardiovascular death | no data | | stroke (fatal and non fatal) | no data | | Coronary event | 0.49 [0.37 0.64] | p=0.04 | 0 | 1600 | 1 | GREACE, | | Coronary death and non fatal MI | no data | | Coronary death | no data | | cardiac death | 0.58 [0.34 0.97] | p=0.04 | 0 | 1600 | 1 | GREACE, | | MACE | no data | | Non fatal MI | no data | | All cause death | 0.58 [0.34 0.97] | p=0.04 | 0 | 1600 | 1 | GREACE, | | non cardiovascular death | 1.50 [0.25 9.00] | p=1.00 | 0 | 1600 | 1 | GREACE, | | Fatal stroke | 0.33 [0.01 8.20] | p=1.00 | 0 | 1600 | 1 | GREACE, | | Haemmorhagic stroke | 1.00 [0.06 16.02] | p=1.00 | 0 | 1600 | 1 | GREACE, | | new-onset diabetes | no data | | Death from cancer | no data | | Rhabdomyolysis | 1.00 [0.02 50.46] | p=1.00 | 0 | 1600 | 1 | GREACE, | | Myopathy | no data | | Cancer | no data | | Adverse events | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| atorvastatin high dose vs angioplasty | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Venous thromboembolism | no data | | cardiovascular events | 0.64 [0.36 1.14] | p=1.00 | 0 | 341 | 1 | AVERT, | | Cardiovascular death | no data | | stroke (fatal and non fatal) | 1.08 [0.02 54.71] | p=1.00 | 0 | 341 | 1 | AVERT, | | Coronary event | no data | | Coronary death and non fatal MI | no data | | Coronary death | 1.08 [0.07 17.40] | p=1.00 | 0 | 341 | 1 | AVERT, | | cardiac death | 1.08 [0.07 17.40] | p=1.00 | 0 | 341 | 1 | AVERT, | | MACE | 0.64 [0.36 1.14] | p=1.00 | 0 | 341 | 1 | AVERT, | | Non fatal MI | 0.86 [0.23 3.27] | p=1.00 | 0 | 341 | 1 | AVERT, | | All cause death | no data | | non cardiovascular death | no data | | Fatal stroke | no data | | Haemmorhagic stroke | no data | | new-onset diabetes | no data | | Death from cancer | no data | | Rhabdomyolysis | no data | | Myopathy | no data | | Cancer | no data | | Adverse events | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| atorvastatin high dose vs atorvastatin | cardiovascular events by 21% (fully demonstrated) Myopathy by 568% (harmful effect) Adverse events by 36% (harmful effect) suggested stroke (fatal and non fatal) by 24% (not demonstrated) suggested Coronary event by 20% (not demonstrated) suggested Coronary death and non fatal MI by 20% (not demonstrated) suggested Non fatal MI by 21% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Venous thromboembolism | no data | | cardiovascular events | 0.79 [0.70 0.91] | p=0.04 | 0 | 10001 | 1 | TNT, | | Cardiovascular death | no data | | stroke (fatal and non fatal) | 0.76 [0.59 0.96] | p=0.04 | 0 | 10001 | 1 | TNT, | | Coronary event | 0.80 [0.69 0.93] | p=0.04 | 0 | 10001 | 1 | TNT, | | Coronary death and non fatal MI | 0.80 [0.69 0.93] | p=0.04 | 0 | 10001 | 1 | TNT, | | Coronary death | 0.80 [0.61 1.04] | p=1.00 | 0 | 10001 | 1 | TNT, | | cardiac death | no data | | MACE | no data | | Non fatal MI | 0.79 [0.67 0.94] | p=0.04 | 0 | 10001 | 1 | TNT, | | All cause death | 1.01 [0.85 1.20] | p=1.00 | 0 | 10001 | 1 | TNT, | | non cardiovascular death | no data | | Fatal stroke | no data | | Haemmorhagic stroke | 0.84 [0.43 1.64] | p=1.00 | 0 | 10001 | 1 | TNT, | | new-onset diabetes | no data | | Death from cancer | no data | | Rhabdomyolysis | 0.67 [0.11 4.00] | p=1.00 | 0 | 10001 | 1 | TNT, | | Myopathy | 6.68 [3.31 13.48] | p=0.04 | 0 | 10001 | 1 | TNT, | | Cancer | no data | | Adverse events | 1.36 [1.16 1.60] | p=0.04 | 0 | 10001 | 1 | TNT, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| atorvastatin high dose vs lovastatin | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Venous thromboembolism | no data | | cardiovascular events | no data | | Cardiovascular death | no data | | stroke (fatal and non fatal) | 0.52 [0.03 8.45] | p=1.00 | 0 | 300 | 1 | Vascular basis, | | Coronary event | no data | | Coronary death and non fatal MI | 2.09 [0.23 18.96] | p=1.00 | 0 | 300 | 1 | Vascular basis, | | Coronary death | no data | | cardiac death | no data | | MACE | 1.57 [0.55 4.44] | p=1.00 | 0 | 300 | 1 | Vascular basis, | | Non fatal MI | no data | | All cause death | 1.57 [0.06 38.85] | p=1.00 | 0 | 300 | 1 | Vascular basis, | | non cardiovascular death | no data | | Fatal stroke | no data | | Haemmorhagic stroke | no data | | new-onset diabetes | no data | | Death from cancer | no data | | Rhabdomyolysis | no data | | Myopathy | no data | | Cancer | no data | | Adverse events | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| atorvastatin high dose vs pravastatin | No demonstrated result suggested MACE by 24% (not demonstrated) suggested All cause death by 67% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Venous thromboembolism | no data | | cardiovascular events | no data | | Cardiovascular death | 0.40 [0.12 1.28] | p=1.00 | 0 | 891 | 1 | SAGE, | | stroke (fatal and non fatal) | 1.07 [0.58 1.96] | p=1.00 | 0 | 5697 | 3 | REVERSAL,PROVE-IT,SAGE, | | Coronary event | no data | | Coronary death and non fatal MI | 0.84 [0.68 1.04] | p=1.00 | 0 | 5697 | 3 | PROVE-IT,REVERSAL,SAGE, | | Coronary death | 0.33 [0.07 1.66] | p=1.00 | 0 | 891 | 1 | SAGE, | | cardiac death | no data | | MACE | 0.76 [0.66 0.87] | p=0.04 | 0 | 5043 | 2 | PROVE-IT,SAGE, | | Non fatal MI | 0.94 [0.47 1.88] | p=1.00 | 0 | 891 | 1 | SAGE, | | All cause death | 0.33 [0.13 0.85] | p=0.04 | 0 | 891 | 1 | SAGE, | | non cardiovascular death | 0.33 [0.07 1.66] | p=1.00 | 0 | 891 | 1 | SAGE, | | Fatal stroke | no data | | Haemmorhagic stroke | no data | | new-onset diabetes | no data | | Death from cancer | 0.20 [0.01 4.17] | p=1.00 | 0 | 891 | 1 | SAGE, | | Rhabdomyolysis | 1.00 [0.10 9.62] | p=1.00 | 0 | 5697 | 3 | PROVE-IT,REVERSAL,SAGE, | | Myopathy | 1.00 [0.06 16.00] | p=1.00 | 0 | 1545 | 2 | REVERSAL,SAGE, | | Cancer | no data | | Adverse events | 1.11 [0.87 1.43] | p=1.00 | 0 | 5697 | 3 | REVERSAL,PROVE-IT,SAGE, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| atorvastatin high dose vs simvastatin | No demonstrated result Myopathy by 802% (harmful effect) Adverse events by 130% (harmful effect) suggested Non fatal MI by 17% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Venous thromboembolism | no data | | cardiovascular events | no data | | Cardiovascular death | no data | | stroke (fatal and non fatal) | 0.87 [0.70 1.09] | p=1.00 | 0 | 8888 | 1 | IDEAL, | | Coronary event | 0.89 [0.77 1.02] | p=1.00 | 0 | 8888 | 1 | IDEAL, | | Coronary death and non fatal MI | 0.89 [0.77 1.02] | p=1.00 | 0 | 8888 | 1 | IDEAL, | | Coronary death | 0.99 [0.80 1.22] | p=1.00 | 0 | 8888 | 1 | IDEAL, | | cardiac death | no data | | MACE | no data | | Non fatal MI | 0.83 [0.70 0.99] | p=0.04 | 0 | 8888 | 1 | IDEAL, | | All cause death | 0.98 [0.84 1.14] | p=1.00 | 0 | 8888 | 1 | IDEAL, | | non cardiovascular death | no data | | Fatal stroke | no data | | Haemmorhagic stroke | no data | | new-onset diabetes | no data | | Death from cancer | 0.89 [0.67 1.16] | p=1.00 | 0 | 8888 | 1 | IDEAL, | | Rhabdomyolysis | 0.67 [0.11 4.00] | p=1.00 | 0 | 8888 | 1 | IDEAL, | | Myopathy | 9.02 [2.09 38.90] | p=0.04 | 0 | 8888 | 1 | IDEAL, | | Cancer | no data | | Adverse events | 2.30 [1.92 2.74] | p=0.04 | 0 | 8888 | 1 | IDEAL, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
Diabetic patients : 6 trials - ASCOT (diabetics sub group) - CARDS - Deutsche Diabetes Dialyse Studie (4D) - ASPEN - TNT (diabetic sub group) - ASPEN
| atorvastatin vs placebo | MACE by 20% (fully demonstrated) suggested cardiovascular events by 13% (not demonstrated) suggested stroke (fatal and non fatal) by 26% (not demonstrated) suggested Coronary event by 22% (not demonstrated) suggested Non fatal MI by 40% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Venous thromboembolism | no data | | cardiovascular events | 0.87 [0.78 0.98] | p=0.04 | 0 | 11448 | 5 | ASCOT (diabetics sub group),CARDS,Deutsche Diabetes Dialyse Studie (4D),ASPEN,ASPEN, | | Cardiovascular death | 0.87 [0.72 1.06] | p=1.00 | 0 | 8916 | 4 | CARDS,Deutsche Diabetes Dialyse Studie (4D),ASPEN,ASPEN, | | stroke (fatal and non fatal) | 0.74 [0.58 0.95] | p=0.04 | 0 | 10193 | 4 | ASCOT (diabetics sub group),CARDS,ASPEN,ASPEN, | | Coronary event | 0.78 [0.66 0.93] | p=0.04 | 0 | 6506 | 3 | CARDS,Deutsche Diabetes Dialyse Studie (4D),ASPEN, | | Coronary death and non fatal MI | no data | | Coronary death | 0.74 [0.40 1.37] | p=1.00 | 0 | 2841 | 1 | CARDS, | | cardiac death | no data | | retinopathy | no data | | vision loss | no data | | MACE | 0.80 [0.67 0.95] | p=0.04 | 0 | 5251 | 2 | CARDS,ASPEN, | | Non fatal MI | 0.60 [0.36 1.00] | p=0.04 | 0 | 2841 | 1 | CARDS, | | Revascularization | no data | | All cause death | 0.91 [0.77 1.07] | p=1.00 | 0 | 6506 | 3 | CARDS,Deutsche Diabetes Dialyse Studie (4D),ASPEN, | | non cardiovascular death | 0.97 [0.75 1.25] | p=1.00 | 0 | 1255 | 1 | Deutsche Diabetes Dialyse Studie (4D), | | Fatal stroke | 0.14 [0.02 1.15] | p=1.00 | 0 | 2841 | 1 | CARDS, | | Haemmorhagic stroke | 0.99 [0.02 49.84] | p=1.00 | 0 | 2841 | 1 | CARDS, | | new-onset diabetes | no data | | Death from cancer | 0.66 [0.37 1.17] | p=1.00 | 0 | 2841 | 1 | CARDS, | | Rhabdomyolysis | 0.99 [0.02 49.84] | p=1.00 | 0 | 2841 | 1 | CARDS, | | Myopathy | 0.99 [0.06 15.81] | p=1.00 | 0 | 2841 | 1 | CARDS, | | Cancer | no data | | Adverse events | 0.94 [0.50 1.77] | p=1.00 | 0 | 2841 | 1 | CARDS, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| atorvastatin high dose vs atorvastatin | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | 0.77 [0.58 1.02] | p=1.00 | 0 | 1501 | 1 | TNT (diabetic sub group), | | Cardiovascular death | no data | | stroke (fatal and non fatal) | 0.70 [0.48 1.01] | p=1.00 | 0 | 1501 | 1 | TNT (diabetic sub group), | | Coronary event | 0.82 [0.60 1.12] | p=1.00 | 0 | 1501 | 1 | TNT (diabetic sub group), | | retinopathy | no data | | vision loss | no data | | All cause death | 1.10 [0.79 1.54] | p=1.00 | 0 | 1501 | 1 | TNT (diabetic sub group), |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
High risk patients with or without LDL cholesterol elevation: 1 trials - ASCOT
| atorvastatin vs placebo | Coronary event by 28% (fully demonstrated) suggested stroke (fatal and non fatal) by 27% (not demonstrated) suggested Coronary death and non fatal MI by 35% (not demonstrated) suggested MACE by 20% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Venous thromboembolism | no data | | cardiovascular events | no data | | Cardiovascular death | 0.90 [0.65 1.23] | p=1.00 | 0 | 10305 | 1 | ASCOT, | | stroke (fatal and non fatal) | 0.73 [0.55 0.96] | p=0.04 | 0 | 10305 | 1 | ASCOT, | | Coronary death and non fatal MI | 0.65 [0.50 0.83] | p=0.04 | 0 | 10305 | 1 | ASCOT, | | Coronary event | 0.72 [0.59 0.87] | p=0.04 | 0 | 10305 | 1 | ASCOT, | | Coronary death | no data | | cardiac death | no data | | MACE | 0.80 [0.69 0.91] | p=0.04 | 0 | 10305 | 1 | ASCOT, | | Non fatal MI | no data | | All cause death | 0.87 [0.71 1.06] | p=1.00 | 0 | 10305 | 1 | ASCOT, | | non cardiovascular death | 0.85 [0.66 1.10] | p=1.00 | 0 | 10305 | 1 | ASCOT, | | Fatal stroke | no data | | Haemmorhagic stroke | no data | | new-onset diabetes | 1.14 [0.89 1.46] | p=1.00 | 0 | 7773 | 1 | ASCOT, | | Death from cancer | no data | | Rhabdomyolysis | 2.98 [0.12 73.22] | p=1.00 | 0 | 10305 | 1 | ASCOT, | | Myopathy | no data | | Cancer | no data | | Adverse events | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
Hypertensive patients: 1 trials - ASCOT
| atorvastatin vs placebo | Coronary event by 28% (fully demonstrated) suggested stroke (fatal and non fatal) by 27% (not demonstrated) suggested Coronary death and non fatal MI by 35% (not demonstrated) suggested MACE by 20% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Venous thromboembolism | no data | | cardiovascular events | no data | | Cardiovascular death | 0.90 [0.65 1.23] | p=1.00 | 0 | 10305 | 1 | ASCOT, | | stroke (fatal and non fatal) | 0.73 [0.55 0.96] | p=0.04 | 0 | 10305 | 1 | ASCOT, | | Coronary death and non fatal MI | 0.65 [0.50 0.83] | p=0.04 | 0 | 10305 | 1 | ASCOT, | | Coronary event | 0.72 [0.59 0.87] | p=0.04 | 0 | 10305 | 1 | ASCOT, | | Coronary death | no data | | cardiac death | no data | | MACE | 0.80 [0.69 0.91] | p=0.04 | 0 | 10305 | 1 | ASCOT, | | Non fatal MI | no data | | All cause death | 0.87 [0.71 1.06] | p=1.00 | 0 | 10305 | 1 | ASCOT, | | non cardiovascular death | 0.85 [0.66 1.10] | p=1.00 | 0 | 10305 | 1 | ASCOT, | | Fatal stroke | no data | | Haemmorhagic stroke | no data | | new-onset diabetes | 1.14 [0.89 1.46] | p=1.00 | 0 | 7773 | 1 | ASCOT, | | Death from cancer | no data | | Rhabdomyolysis | 2.98 [0.12 73.22] | p=1.00 | 0 | 10305 | 1 | ASCOT, | | Myopathy | no data | | Cancer | no data | | Adverse events | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
Patient with related disease: 1 trials - SALTIRE
| atorvastatin vs placebo | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
Patients with prior MI or with CHD: 12 trials - REVERSAL - PROVE-IT - PROVE IT - TIMI 22 - MIRACL - TNT - IDEAL - Colivicchi - ESTABLISH - Vascular basis - SAGE - GREACE - macin
| atorvastatin vs placebo | No demonstrated result suggested recurrent angina by 26% (not demonstrated) suggested Non fatal stroke by 59% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Deaths or MI | 0.92 [0.73 1.16] | p=1.00 | 0 | 3086 | 1 | MIRACL, | | cardiovascular events at 1 month | 1.06 [0.79 1.41] | p=1.00 | 0 | 3086 | 1 | MIRACL, | | cardiovascular events at 4 months | 0.89 [0.71 1.12] | p=1.00 | 0 | 3086 | 1 | MIRACL, | | PTCA | 1.06 [0.83 1.34] | p=1.00 | 0 | 3086 | 1 | MIRACL, | | recurrent angina | 0.74 [0.56 0.97] | p=0.04 | 0 | 3086 | 1 | MIRACL, | | cardiovascular events | 0.92 [0.73 1.16] | p=1.00 | 0 | 3086 | 1 | MIRACL, | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | 0.50 [0.25 1.01] | p=1.00 | 0 | 3086 | 1 | MIRACL, | | cardiac death | 0.86 [0.58 1.25] | p=1.00 | 0 | 3086 | 1 | MIRACL, | | CABG | 0.97 [0.74 1.28] | p=1.00 | 0 | 3086 | 1 | MIRACL, | | Fatal MI | 0.95 [0.49 1.85] | p=1.00 | 0 | 3086 | 1 | MIRACL, | | Non fatal MI | 0.90 [0.68 1.19] | p=1.00 | 0 | 3086 | 1 | MIRACL, | | Revascularization | 1.02 [0.84 1.24] | p=1.00 | 0 | 3086 | 1 | MIRACL, | | All cause death | 0.95 [0.67 1.34] | p=1.00 | 0 | 3086 | 1 | MIRACL, | | Non fatal stroke | 0.41 [0.19 0.90] | p=0.04 | 0 | 3086 | 1 | MIRACL, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| atorvastatin vs pravastatin | No demonstrated result suggested cardiovascular events by 24% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Deaths or MI | no data | | cardiovascular events at 1 month | no data | | cardiovascular events at 4 months | no data | | PTCA | no data | | recurrent angina | no data | | cardiovascular events | 0.76 [0.66 0.88] | p=0.04 | 0 | 4152 | 1 | PROVE IT - TIMI 22, | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | cardiac death | no data | | CABG | no data | | Fatal MI | no data | | Non fatal MI | no data | | Revascularization | no data | | All cause death | 0.72 [0.50 1.03] | p=1.00 | 0 | 4152 | 1 | PROVE IT - TIMI 22, | | Non fatal stroke | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| atorvastatin vs usual care | No demonstrated result suggested Coronary event by 51% (not demonstrated) suggested cardiac death by 41% (not demonstrated) suggested All cause death by 42% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Deaths or MI | no data | | cardiovascular events at 1 month | 0.15 [0.01 2.93] | p=1.00 | 0 | 81 | 1 | Colivicchi, | | cardiovascular events at 4 months | 0.53 [0.17 1.64] | p=1.00 | 0 | 151 | 2 | Colivicchi,ESTABLISH, | | PTCA | no data | | recurrent angina | no data | | Venous thromboembolism | no data | | cardiovascular events | 0.53 [0.17 1.64] | p=1.00 | 0 | 151 | 2 | Colivicchi,ESTABLISH, | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | 0.62 [0.08 4.92] | p=1.00 | 0 | 151 | 2 | Colivicchi,ESTABLISH, | | Coronary event | 0.49 [0.37 0.64] | p=0.04 | 0 | 1600 | 1 | GREACE, | | Coronary death and non fatal MI | no data | | Coronary death | no data | | cardiac death | 0.59 [0.36 0.97] | p=0.04 | 0 | 1751 | 3 | Colivicchi,ESTABLISH,GREACE, | | MACE | no data | | CABG | no data | | Fatal MI | 0.73 [0.14 3.89] | p=1.00 | 0 | 151 | 2 | Colivicchi,ESTABLISH, | | Non fatal MI | 0.48 [0.13 1.85] | p=1.00 | 0 | 151 | 2 | Colivicchi,ESTABLISH, | | Revascularization | 1.00 [0.34 2.93] | p=1.00 | 0 | 151 | 2 | Colivicchi,ESTABLISH, | | All cause death | 0.58 [0.36 0.95] | p=0.04 | 0 | 1751 | 3 | Colivicchi,ESTABLISH,GREACE, | | non cardiovascular death | 1.50 [0.25 9.00] | p=1.00 | 0 | 1600 | 1 | GREACE, | | Fatal stroke | 0.33 [0.01 8.20] | p=1.00 | 0 | 1600 | 1 | GREACE, | | Non fatal stroke | no data | | Haemmorhagic stroke | 1.00 [0.06 16.02] | p=1.00 | 0 | 1600 | 1 | GREACE, | | new-onset diabetes | no data | | Death from cancer | no data | | Rhabdomyolysis | 1.00 [0.02 50.46] | p=1.00 | 0 | 1600 | 1 | GREACE, | | Myopathy | no data | | Cancer | no data | | Adverse events | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| atorvastatin high dose vs atorvastatin | cardiovascular events by 21% (fully demonstrated) Myopathy by 568% (harmful effect) Adverse events by 36% (harmful effect) suggested stroke (fatal and non fatal) by 24% (not demonstrated) suggested Coronary event by 20% (not demonstrated) suggested Coronary death and non fatal MI by 20% (not demonstrated) suggested Non fatal MI by 21% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Venous thromboembolism | no data | | cardiovascular events | 0.79 [0.70 0.91] | p=0.04 | 0 | 10001 | 1 | TNT, | | Cardiovascular death | no data | | stroke (fatal and non fatal) | 0.76 [0.59 0.96] | p=0.04 | 0 | 10001 | 1 | TNT, | | Coronary event | 0.80 [0.69 0.93] | p=0.04 | 0 | 10001 | 1 | TNT, | | Coronary death and non fatal MI | 0.80 [0.69 0.93] | p=0.04 | 0 | 10001 | 1 | TNT, | | Coronary death | 0.80 [0.61 1.04] | p=1.00 | 0 | 10001 | 1 | TNT, | | cardiac death | no data | | MACE | no data | | Non fatal MI | 0.79 [0.67 0.94] | p=0.04 | 0 | 10001 | 1 | TNT, | | All cause death | 1.01 [0.85 1.20] | p=1.00 | 0 | 10001 | 1 | TNT, | | non cardiovascular death | no data | | Fatal stroke | no data | | Haemmorhagic stroke | 0.84 [0.43 1.64] | p=1.00 | 0 | 10001 | 1 | TNT, | | new-onset diabetes | no data | | Death from cancer | no data | | Rhabdomyolysis | 0.67 [0.11 4.00] | p=1.00 | 0 | 10001 | 1 | TNT, | | Myopathy | 6.68 [3.31 13.48] | p=0.04 | 0 | 10001 | 1 | TNT, | | Cancer | no data | | Adverse events | 1.36 [1.16 1.60] | p=0.04 | 0 | 10001 | 1 | TNT, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| atorvastatin high dose vs lovastatin | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Venous thromboembolism | no data | | cardiovascular events | no data | | Cardiovascular death | no data | | stroke (fatal and non fatal) | 0.52 [0.03 8.45] | p=1.00 | 0 | 300 | 1 | Vascular basis, | | Coronary event | no data | | Coronary death and non fatal MI | 2.09 [0.23 18.96] | p=1.00 | 0 | 300 | 1 | Vascular basis, | | Coronary death | no data | | cardiac death | no data | | MACE | 1.57 [0.55 4.44] | p=1.00 | 0 | 300 | 1 | Vascular basis, | | Non fatal MI | no data | | All cause death | 1.57 [0.06 38.85] | p=1.00 | 0 | 300 | 1 | Vascular basis, | | non cardiovascular death | no data | | Fatal stroke | no data | | Haemmorhagic stroke | no data | | new-onset diabetes | no data | | Death from cancer | no data | | Rhabdomyolysis | no data | | Myopathy | no data | | Cancer | no data | | Adverse events | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| atorvastatin high dose vs pravastatin | No demonstrated result suggested MACE by 24% (not demonstrated) suggested All cause death by 67% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Venous thromboembolism | no data | | cardiovascular events | no data | | Cardiovascular death | 0.40 [0.12 1.28] | p=1.00 | 0 | 891 | 1 | SAGE, | | stroke (fatal and non fatal) | 1.07 [0.58 1.96] | p=1.00 | 0 | 5697 | 3 | REVERSAL,PROVE-IT,SAGE, | | Coronary event | no data | | Coronary death and non fatal MI | 0.84 [0.68 1.04] | p=1.00 | 0 | 5697 | 3 | PROVE-IT,REVERSAL,SAGE, | | Coronary death | 0.33 [0.07 1.66] | p=1.00 | 0 | 891 | 1 | SAGE, | | cardiac death | no data | | MACE | 0.76 [0.66 0.87] | p=0.04 | 0 | 5043 | 2 | PROVE-IT,SAGE, | | Non fatal MI | 0.94 [0.47 1.88] | p=1.00 | 0 | 891 | 1 | SAGE, | | All cause death | 0.33 [0.13 0.85] | p=0.04 | 0 | 891 | 1 | SAGE, | | non cardiovascular death | 0.33 [0.07 1.66] | p=1.00 | 0 | 891 | 1 | SAGE, | | Fatal stroke | no data | | Haemmorhagic stroke | no data | | new-onset diabetes | no data | | Death from cancer | 0.20 [0.01 4.17] | p=1.00 | 0 | 891 | 1 | SAGE, | | Rhabdomyolysis | 1.00 [0.10 9.62] | p=1.00 | 0 | 5697 | 3 | PROVE-IT,REVERSAL,SAGE, | | Myopathy | 1.00 [0.06 16.00] | p=1.00 | 0 | 1545 | 2 | REVERSAL,SAGE, | | Cancer | no data | | Adverse events | 1.11 [0.87 1.43] | p=1.00 | 0 | 5697 | 3 | REVERSAL,PROVE-IT,SAGE, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| atorvastatin high dose vs simvastatin | No demonstrated result Myopathy by 802% (harmful effect) Adverse events by 130% (harmful effect) suggested Non fatal MI by 17% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Venous thromboembolism | no data | | cardiovascular events | no data | | Cardiovascular death | no data | | stroke (fatal and non fatal) | 0.87 [0.70 1.09] | p=1.00 | 0 | 8888 | 1 | IDEAL, | | Coronary event | 0.89 [0.77 1.02] | p=1.00 | 0 | 8888 | 1 | IDEAL, | | Coronary death and non fatal MI | 0.89 [0.77 1.02] | p=1.00 | 0 | 8888 | 1 | IDEAL, | | Coronary death | 0.99 [0.80 1.22] | p=1.00 | 0 | 8888 | 1 | IDEAL, | | cardiac death | no data | | MACE | no data | | Non fatal MI | 0.83 [0.70 0.99] | p=0.04 | 0 | 8888 | 1 | IDEAL, | | All cause death | 0.98 [0.84 1.14] | p=1.00 | 0 | 8888 | 1 | IDEAL, | | non cardiovascular death | no data | | Fatal stroke | no data | | Haemmorhagic stroke | no data | | new-onset diabetes | no data | | Death from cancer | 0.89 [0.67 1.16] | p=1.00 | 0 | 8888 | 1 | IDEAL, | | Rhabdomyolysis | 0.67 [0.11 4.00] | p=1.00 | 0 | 8888 | 1 | IDEAL, | | Myopathy | 9.02 [2.09 38.90] | p=0.04 | 0 | 8888 | 1 | IDEAL, | | Cancer | no data | | Adverse events | 2.30 [1.92 2.74] | p=0.04 | 0 | 8888 | 1 | IDEAL, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
Patients with renal insufficiency (on hemodialysis or transplant): 1 trials - Deutsche Diabetes Dialyse Studie (4D)
| atorvastatin vs placebo | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | 0.96 [0.76 1.20] | p=1.00 | 0 | 1255 | 1 | Deutsche Diabetes Dialyse Studie (4D), | | Cardiovascular death | 0.83 [0.64 1.09] | p=1.00 | 0 | 1255 | 1 | Deutsche Diabetes Dialyse Studie (4D), | | Coronary event | 0.86 [0.68 1.08] | p=1.00 | 0 | 1255 | 1 | Deutsche Diabetes Dialyse Studie (4D), | | Revascularization | no data | | All cause death | 0.95 [0.76 1.19] | p=1.00 | 0 | 1255 | 1 | Deutsche Diabetes Dialyse Studie (4D), | | non cardiovascular death | 0.97 [0.75 1.25] | p=1.00 | 0 | 1255 | 1 | Deutsche Diabetes Dialyse Studie (4D), |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
Post stroke (or TIA) : 1 trials - SPARCL
| atorvastatin vs placebo | No demonstrated result suggested TIA by 26% (not demonstrated) suggested cardiovascular events by 18% (not demonstrated) suggested stroke or TIA by 21% (not demonstrated) suggested Coronary event by 32% (not demonstrated) suggested Fatal stroke by 41% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| TIA | 0.74 [0.59 0.91] | p=0.04 | 0 | 4731 | 1 | SPARCL, | | cardiovascular events | 0.82 [0.70 0.96] | p=0.04 | 0 | 4731 | 1 | SPARCL, | | Cardiovascular death | 0.80 [0.59 1.08] | p=1.00 | 0 | 4731 | 1 | SPARCL, | | stroke (fatal and non fatal) | 0.85 [0.72 1.02] | p=1.00 | 0 | 4731 | 1 | SPARCL, | | stroke or TIA | 0.79 [0.68 0.92] | p=0.04 | 0 | 4731 | 1 | SPARCL, | | Coronary event | 0.68 [0.51 0.90] | p=0.04 | 0 | 4731 | 1 | SPARCL, | | All cause death | 1.02 [0.84 1.25] | p=1.00 | 0 | 4731 | 1 | SPARCL, | | Fatal stroke | 0.59 [0.35 0.97] | p=0.04 | 0 | 4731 | 1 | SPARCL, | | Non fatal stroke | 0.88 [0.74 1.06] | p=1.00 | 0 | 4731 | 1 | SPARCL, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
Primary prevention: 4 trials - CARDS - ASCOT - Mohler - ASPEN (primary prevention sub group)
| atorvastatin vs placebo | Coronary event by 24% (fully demonstrated) MACE by 24% (fully demonstrated) suggested cardiovascular events by 20% (not demonstrated) suggested stroke (fatal and non fatal) by 28% (not demonstrated) suggested Coronary death and non fatal MI by 35% (not demonstrated) suggested Non fatal MI by 40% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Venous thromboembolism | no data | | cardiovascular events | 0.80 [0.64 0.99] | p=0.04 | 0 | 4746 | 2 | CARDS,ASPEN (primary prevention sub group), | | Cardiovascular death | 0.89 [0.69 1.15] | p=1.00 | 0 | 15051 | 3 | CARDS,ASCOT,ASPEN (primary prevention sub group), | | stroke (fatal and non fatal) | 0.72 [0.58 0.90] | p=0.04 | 0 | 15051 | 3 | CARDS,ASCOT,ASPEN (primary prevention sub group), | | Coronary event | 0.76 [0.66 0.88] | p=0.04 | 0 | 15051 | 3 | CARDS,ASCOT,ASPEN (primary prevention sub group), | | Coronary death and non fatal MI | 0.65 [0.50 0.83] | p=0.04 | 0 | 10305 | 1 | ASCOT, | | Coronary death | 0.74 [0.40 1.37] | p=1.00 | 0 | 2841 | 1 | CARDS, | | cardiac death | no data | | MACE | 0.76 [0.67 0.87] | p=0.04 | 0 | 13146 | 2 | CARDS,ASCOT, | | Non fatal MI | 0.60 [0.36 1.00] | p=0.04 | 0 | 2841 | 1 | CARDS, | | All cause death | 0.86 [0.73 1.01] | p=1.00 | 0 | 15051 | 3 | CARDS,ASCOT,ASPEN (primary prevention sub group), | | non cardiovascular death | 0.86 [0.68 1.08] | p=1.00 | 0 | 12210 | 2 | ASCOT,ASPEN (primary prevention sub group), | | Fatal stroke | 0.14 [0.02 1.15] | p=1.00 | 0 | 2841 | 1 | CARDS, | | Haemmorhagic stroke | 0.99 [0.02 49.84] | p=1.00 | 0 | 2841 | 1 | CARDS, | | new-onset diabetes | 1.14 [0.89 1.46] | p=1.00 | 0 | 7773 | 1 | ASCOT, | | Death from cancer | 0.66 [0.37 1.17] | p=1.00 | 0 | 2841 | 1 | CARDS, | | Rhabdomyolysis | 1.92 [0.16 22.88] | p=1.00 | 0 | 13146 | 2 | CARDS,ASCOT, | | Myopathy | 0.99 [0.06 15.81] | p=1.00 | 0 | 2841 | 1 | CARDS, | | Cancer | no data | | Adverse events | 0.94 [0.50 1.77] | p=1.00 | 0 | 2841 | 1 | CARDS, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
Secondary prevention: 8 trials - REVERSAL - AVERT - TNT - IDEAL - Vascular basis - SAGE - GREACE - Mohler
| atorvastatin vs placebo | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Venous thromboembolism | no data | | cardiovascular events | no data | | Cardiovascular death | no data | | stroke (fatal and non fatal) | no data | | Coronary event | no data | | Coronary death and non fatal MI | no data | | Coronary death | no data | | cardiac death | no data | | MACE | no data | | Non fatal MI | no data | | All cause death | no data | | non cardiovascular death | no data | | Fatal stroke | no data | | Haemmorhagic stroke | no data | | new-onset diabetes | no data | | Death from cancer | no data | | Rhabdomyolysis | no data | | Myopathy | no data | | Cancer | no data | | Adverse events | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| atorvastatin vs usual care | No demonstrated result suggested Coronary event by 51% (not demonstrated) suggested cardiac death by 43% (not demonstrated) suggested All cause death by 43% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Venous thromboembolism | no data | | cardiovascular events | no data | | Cardiovascular death | no data | | stroke (fatal and non fatal) | no data | | Coronary event | 0.49 [0.37 0.64] | p=0.04 | 0 | 1600 | 1 | GREACE, | | Coronary death and non fatal MI | no data | | Coronary death | no data | | cardiac death | 0.58 [0.34 0.97] | p=0.04 | 0 | 1600 | 1 | GREACE, | | MACE | no data | | Non fatal MI | no data | | All cause death | 0.58 [0.34 0.97] | p=0.04 | 0 | 1600 | 1 | GREACE, | | non cardiovascular death | 1.50 [0.25 9.00] | p=1.00 | 0 | 1600 | 1 | GREACE, | | Fatal stroke | 0.33 [0.01 8.20] | p=1.00 | 0 | 1600 | 1 | GREACE, | | Haemmorhagic stroke | 1.00 [0.06 16.02] | p=1.00 | 0 | 1600 | 1 | GREACE, | | new-onset diabetes | no data | | Death from cancer | no data | | Rhabdomyolysis | 1.00 [0.02 50.46] | p=1.00 | 0 | 1600 | 1 | GREACE, | | Myopathy | no data | | Cancer | no data | | Adverse events | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| atorvastatin high dose vs angioplasty | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Venous thromboembolism | no data | | cardiovascular events | 0.64 [0.36 1.14] | p=1.00 | 0 | 341 | 1 | AVERT, | | Cardiovascular death | no data | | stroke (fatal and non fatal) | 1.08 [0.02 54.71] | p=1.00 | 0 | 341 | 1 | AVERT, | | Coronary event | no data | | Coronary death and non fatal MI | no data | | Coronary death | 1.08 [0.07 17.40] | p=1.00 | 0 | 341 | 1 | AVERT, | | cardiac death | 1.08 [0.07 17.40] | p=1.00 | 0 | 341 | 1 | AVERT, | | MACE | 0.64 [0.36 1.14] | p=1.00 | 0 | 341 | 1 | AVERT, | | Non fatal MI | 0.86 [0.23 3.27] | p=1.00 | 0 | 341 | 1 | AVERT, | | All cause death | no data | | non cardiovascular death | no data | | Fatal stroke | no data | | Haemmorhagic stroke | no data | | new-onset diabetes | no data | | Death from cancer | no data | | Rhabdomyolysis | no data | | Myopathy | no data | | Cancer | no data | | Adverse events | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| atorvastatin high dose vs atorvastatin | cardiovascular events by 21% (fully demonstrated) Myopathy by 568% (harmful effect) Adverse events by 36% (harmful effect) suggested stroke (fatal and non fatal) by 24% (not demonstrated) suggested Coronary event by 20% (not demonstrated) suggested Coronary death and non fatal MI by 20% (not demonstrated) suggested Non fatal MI by 21% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Venous thromboembolism | no data | | cardiovascular events | 0.79 [0.70 0.91] | p=0.04 | 0 | 10001 | 1 | TNT, | | Cardiovascular death | no data | | stroke (fatal and non fatal) | 0.76 [0.59 0.96] | p=0.04 | 0 | 10001 | 1 | TNT, | | Coronary event | 0.80 [0.69 0.93] | p=0.04 | 0 | 10001 | 1 | TNT, | | Coronary death and non fatal MI | 0.80 [0.69 0.93] | p=0.04 | 0 | 10001 | 1 | TNT, | | Coronary death | 0.80 [0.61 1.04] | p=1.00 | 0 | 10001 | 1 | TNT, | | cardiac death | no data | | MACE | no data | | Non fatal MI | 0.79 [0.67 0.94] | p=0.04 | 0 | 10001 | 1 | TNT, | | All cause death | 1.01 [0.85 1.20] | p=1.00 | 0 | 10001 | 1 | TNT, | | non cardiovascular death | no data | | Fatal stroke | no data | | Haemmorhagic stroke | 0.84 [0.43 1.64] | p=1.00 | 0 | 10001 | 1 | TNT, | | new-onset diabetes | no data | | Death from cancer | no data | | Rhabdomyolysis | 0.67 [0.11 4.00] | p=1.00 | 0 | 10001 | 1 | TNT, | | Myopathy | 6.68 [3.31 13.48] | p=0.04 | 0 | 10001 | 1 | TNT, | | Cancer | no data | | Adverse events | 1.36 [1.16 1.60] | p=0.04 | 0 | 10001 | 1 | TNT, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| atorvastatin high dose vs lovastatin | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Venous thromboembolism | no data | | cardiovascular events | no data | | Cardiovascular death | no data | | stroke (fatal and non fatal) | 0.52 [0.03 8.45] | p=1.00 | 0 | 300 | 1 | Vascular basis, | | Coronary event | no data | | Coronary death and non fatal MI | 2.09 [0.23 18.96] | p=1.00 | 0 | 300 | 1 | Vascular basis, | | Coronary death | no data | | cardiac death | no data | | MACE | 1.57 [0.55 4.44] | p=1.00 | 0 | 300 | 1 | Vascular basis, | | Non fatal MI | no data | | All cause death | 1.57 [0.06 38.85] | p=1.00 | 0 | 300 | 1 | Vascular basis, | | non cardiovascular death | no data | | Fatal stroke | no data | | Haemmorhagic stroke | no data | | new-onset diabetes | no data | | Death from cancer | no data | | Rhabdomyolysis | no data | | Myopathy | no data | | Cancer | no data | | Adverse events | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| atorvastatin high dose vs pravastatin | No demonstrated result suggested All cause death by 67% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Venous thromboembolism | no data | | cardiovascular events | no data | | Cardiovascular death | 0.40 [0.12 1.28] | p=1.00 | 0 | 891 | 1 | SAGE, | | stroke (fatal and non fatal) | 0.52 [0.09 2.99] | p=1.00 | 0 | 1545 | 2 | REVERSAL,SAGE, | | Coronary event | no data | | Coronary death and non fatal MI | 0.76 [0.45 1.29] | p=1.00 | 0 | 1545 | 2 | REVERSAL,SAGE, | | Coronary death | 0.33 [0.07 1.66] | p=1.00 | 0 | 891 | 1 | SAGE, | | cardiac death | no data | | MACE | 0.72 [0.46 1.13] | p=1.00 | 0 | 891 | 1 | SAGE, | | Non fatal MI | 0.94 [0.47 1.88] | p=1.00 | 0 | 891 | 1 | SAGE, | | All cause death | 0.33 [0.13 0.85] | p=0.04 | 0 | 891 | 1 | SAGE, | | non cardiovascular death | 0.33 [0.07 1.66] | p=1.00 | 0 | 891 | 1 | SAGE, | | Fatal stroke | no data | | Haemmorhagic stroke | no data | | new-onset diabetes | no data | | Death from cancer | 0.20 [0.01 4.17] | p=1.00 | 0 | 891 | 1 | SAGE, | | Rhabdomyolysis | 1.00 [0.06 16.00] | p=1.00 | 0 | 1545 | 2 | REVERSAL,SAGE, | | Myopathy | 1.00 [0.06 16.00] | p=1.00 | 0 | 1545 | 2 | REVERSAL,SAGE, | | Cancer | no data | | Adverse events | 1.01 [0.71 1.44] | p=1.00 | 0 | 1545 | 2 | REVERSAL,SAGE, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| atorvastatin high dose vs simvastatin | No demonstrated result Myopathy by 802% (harmful effect) Adverse events by 130% (harmful effect) suggested Non fatal MI by 17% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Venous thromboembolism | no data | | cardiovascular events | no data | | Cardiovascular death | no data | | stroke (fatal and non fatal) | 0.87 [0.70 1.09] | p=1.00 | 0 | 8888 | 1 | IDEAL, | | Coronary event | 0.89 [0.77 1.02] | p=1.00 | 0 | 8888 | 1 | IDEAL, | | Coronary death and non fatal MI | 0.89 [0.77 1.02] | p=1.00 | 0 | 8888 | 1 | IDEAL, | | Coronary death | 0.99 [0.80 1.22] | p=1.00 | 0 | 8888 | 1 | IDEAL, | | cardiac death | no data | | MACE | no data | | Non fatal MI | 0.83 [0.70 0.99] | p=0.04 | 0 | 8888 | 1 | IDEAL, | | All cause death | 0.98 [0.84 1.14] | p=1.00 | 0 | 8888 | 1 | IDEAL, | | non cardiovascular death | no data | | Fatal stroke | no data | | Haemmorhagic stroke | no data | | new-onset diabetes | no data | | Death from cancer | 0.89 [0.67 1.16] | p=1.00 | 0 | 8888 | 1 | IDEAL, | | Rhabdomyolysis | 0.67 [0.11 4.00] | p=1.00 | 0 | 8888 | 1 | IDEAL, | | Myopathy | 9.02 [2.09 38.90] | p=0.04 | 0 | 8888 | 1 | IDEAL, | | Cancer | no data | | Adverse events | 2.30 [1.92 2.74] | p=0.04 | 0 | 8888 | 1 | IDEAL, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
Women: 1 trials - ASCOT (women subgroup)
| Atorvastatin vs placebo | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | 1.10 [0.57 2.13] | p=1.00 | 0 | 1942 | 1 | ASCOT (women subgroup) , | | Coronary event | 1.10 [0.57 2.13] | p=1.00 | 0 | 1942 | 1 | ASCOT (women subgroup) , | | Cancer | no data | | All cause death | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| atorvastatin vs placebo | MACE by 35% (fully demonstrated) suggested cardiovascular events by 19% (not demonstrated) suggested stroke (fatal and non fatal) by 31% (not demonstrated) suggested Coronary event by 35% (not demonstrated) suggested Non fatal MI by 40% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Venous thromboembolism | no data | | cardiovascular events | 0.81 [0.68 0.96] | p=0.04 | 0 | 7783 | 3 | ASCOT (diabetics sub group),CARDS,ASPEN, | | Cardiovascular death | 0.86 [0.60 1.23] | p=1.00 | 0 | 5251 | 2 | CARDS,ASPEN, | | stroke (fatal and non fatal) | 0.69 [0.52 0.93] | p=0.04 | 0 | 7783 | 3 | ASCOT (diabetics sub group),CARDS,ASPEN, | | Coronary event | 0.65 [0.46 0.94] | p=0.04 | 0 | 2841 | 1 | CARDS, | | Coronary death and non fatal MI | no data | | Coronary death | 0.74 [0.40 1.37] | p=1.00 | 0 | 2841 | 1 | CARDS, | | cardiac death | no data | | retinopathy | no data | | vision loss | no data | | MACE | 0.65 [0.48 0.86] | p=0.04 | 0 | 2841 | 1 | CARDS, | | Non fatal MI | 0.60 [0.36 1.00] | p=0.04 | 0 | 2841 | 1 | CARDS, | | All cause death | 0.86 [0.68 1.10] | p=1.00 | 0 | 5251 | 2 | CARDS,ASPEN, | | non cardiovascular death | no data | | Fatal stroke | 0.14 [0.02 1.15] | p=1.00 | 0 | 2841 | 1 | CARDS, | | Haemmorhagic stroke | 0.99 [0.02 49.84] | p=1.00 | 0 | 2841 | 1 | CARDS, | | new-onset diabetes | no data | | Death from cancer | 0.66 [0.37 1.17] | p=1.00 | 0 | 2841 | 1 | CARDS, | | Rhabdomyolysis | 0.99 [0.02 49.84] | p=1.00 | 0 | 2841 | 1 | CARDS, | | Myopathy | 0.99 [0.06 15.81] | p=1.00 | 0 | 2841 | 1 | CARDS, | | Cancer | no data | | Adverse events | 0.94 [0.50 1.77] | p=1.00 | 0 | 2841 | 1 | CARDS, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| atorvastatin high dose vs atorvastatin | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | 0.77 [0.58 1.02] | p=1.00 | 0 | 1501 | 1 | TNT (diabetic sub group), | | Cardiovascular death | no data | | stroke (fatal and non fatal) | 0.70 [0.48 1.01] | p=1.00 | 0 | 1501 | 1 | TNT (diabetic sub group), | | Coronary event | 0.82 [0.60 1.12] | p=1.00 | 0 | 1501 | 1 | TNT (diabetic sub group), | | retinopathy | no data | | vision loss | no data | | All cause death | 1.10 [0.79 1.54] | p=1.00 | 0 | 1501 | 1 | TNT (diabetic sub group), |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| atorvastatin vs control | No demonstrated result suggested MI (CK-MB >3x ULN at 6 and 12 hours after PCI) by 44% (not demonstrated) suggested MI (troponin I >3x ULN at 6 and 12 hours after PCI) by 44% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| MI (CK-MB >3x ULN at 6 and 12 hours after PCI) | 0.56 [0.40 0.79] | p=0.04 | 0 | 668 | 1 | NAPLES II (Briguori), | | MI (troponin I >3x ULN at 6 and 12 hours after PCI) | 0.56 [0.35 0.91] | p=0.04 | 0 | 668 | 1 | NAPLES II (Briguori), | | Cardiovascular death | no data | | stroke (fatal and non fatal) | no data | | MACE | no data | | Non fatal MI | no data | | Revascularization | no data | | All cause death | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| atorvastatin vs placebo | No demonstrated result suggested stroke (fatal and non fatal) by 71% (not demonstrated) suggested Non fatal MI by 71% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| MI (CK-MB >3x ULN at 6 and 12 hours after PCI) | no data | | MI (troponin I >3x ULN at 6 and 12 hours after PCI) | no data | | Cardiovascular death | no data | | stroke (fatal and non fatal) | 0.29 [0.09 0.92] | p=0.04 | 0 | 153 | 1 | ARMYDA, | | MACE | no data | | Non fatal MI | 0.29 [0.09 0.92] | p=0.04 | 0 | 153 | 1 | ARMYDA, | | Revascularization | no data | | All cause death | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| atorvastatin vs usual care | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| MI (CK-MB >3x ULN at 6 and 12 hours after PCI) | no data | | MI (troponin I >3x ULN at 6 and 12 hours after PCI) | no data | | Cardiovascular death | 1.02 [0.02 51.95] | p=1.00 | 0 | 131 | 1 | GAIN, | | stroke (fatal and non fatal) | 5.08 [0.24 107.86] | p=1.00 | 0 | 131 | 1 | GAIN, | | MACE | no data | | Non fatal MI | 0.20 [0.01 4.31] | p=1.00 | 0 | 131 | 1 | GAIN, | | Revascularization | 0.44 [0.17 1.17] | p=1.00 | 0 | 131 | 1 | GAIN, | | All cause death | 1.02 [0.02 51.95] | p=1.00 | 0 | 131 | 1 | GAIN, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| atorvastatin reload vs placebo | No demonstrated result suggested MACE by 61% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| MI (CK-MB >3x ULN at 6 and 12 hours after PCI) | no data | | MI (troponin I >3x ULN at 6 and 12 hours after PCI) | no data | | Cardiovascular death | no data | | stroke (fatal and non fatal) | no data | | MACE | 0.39 [0.16 0.95] | p=0.04 | 0 | 457 | 1 | ARMYDA-RECAPTURE, | | Non fatal MI | 0.41 [0.17 1.01] | p=1.00 | 0 | 383 | 1 | ARMYDA-RECAPTURE, | | Revascularization | 0.33 [0.01 8.19] | p=1.00 | 0 | 383 | 1 | ARMYDA-RECAPTURE, | | All cause death | 0.33 [0.01 8.19] | p=1.00 | 0 | 383 | 1 | ARMYDA-RECAPTURE, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| atorvastatin high dose vs atorvastatin | cardiovascular events by 21% (fully demonstrated) Myopathy by 568% (harmful effect) Adverse events by 36% (harmful effect) suggested stroke (fatal and non fatal) by 24% (not demonstrated) suggested Coronary event by 20% (not demonstrated) suggested Coronary death and non fatal MI by 20% (not demonstrated) suggested Non fatal MI by 21% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Venous thromboembolism | no data | | cardiovascular events | 0.79 [0.70 0.91] | p=0.04 | 0 | 10001 | 1 | TNT, | | Cardiovascular death | no data | | stroke (fatal and non fatal) | 0.76 [0.59 0.96] | p=0.04 | 0 | 10001 | 1 | TNT, | | Coronary event | 0.80 [0.69 0.93] | p=0.04 | 0 | 10001 | 1 | TNT, | | Coronary death and non fatal MI | 0.80 [0.69 0.93] | p=0.04 | 0 | 10001 | 1 | TNT, | | Coronary death | 0.80 [0.61 1.04] | p=1.00 | 0 | 10001 | 1 | TNT, | | cardiac death | no data | | MACE | no data | | Non fatal MI | 0.79 [0.67 0.94] | p=0.04 | 0 | 10001 | 1 | TNT, | | All cause death | 1.01 [0.85 1.20] | p=1.00 | 0 | 10001 | 1 | TNT, | | non cardiovascular death | no data | | Fatal stroke | no data | | Haemmorhagic stroke | 0.84 [0.43 1.64] | p=1.00 | 0 | 10001 | 1 | TNT, | | new-onset diabetes | no data | | Death from cancer | no data | | Rhabdomyolysis | 0.67 [0.11 4.00] | p=1.00 | 0 | 10001 | 1 | TNT, | | Myopathy | 6.68 [3.31 13.48] | p=0.04 | 0 | 10001 | 1 | TNT, | | Cancer | no data | | Adverse events | 1.36 [1.16 1.60] | p=0.04 | 0 | 10001 | 1 | TNT, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| atorvastatin high dose vs lovastatin | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Venous thromboembolism | no data | | cardiovascular events | no data | | Cardiovascular death | no data | | stroke (fatal and non fatal) | 0.52 [0.03 8.45] | p=1.00 | 0 | 300 | 1 | Vascular basis, | | Coronary event | no data | | Coronary death and non fatal MI | 2.09 [0.23 18.96] | p=1.00 | 0 | 300 | 1 | Vascular basis, | | Coronary death | no data | | cardiac death | no data | | MACE | 1.57 [0.55 4.44] | p=1.00 | 0 | 300 | 1 | Vascular basis, | | Non fatal MI | no data | | All cause death | 1.57 [0.06 38.85] | p=1.00 | 0 | 300 | 1 | Vascular basis, | | non cardiovascular death | no data | | Fatal stroke | no data | | Haemmorhagic stroke | no data | | new-onset diabetes | no data | | Death from cancer | no data | | Rhabdomyolysis | no data | | Myopathy | no data | | Cancer | no data | | Adverse events | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| atorvastatin high dose vs pravastatin | No demonstrated result suggested All cause death by 67% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Venous thromboembolism | no data | | cardiovascular events | no data | | Cardiovascular death | 0.40 [0.12 1.28] | p=1.00 | 0 | 891 | 1 | SAGE, | | stroke (fatal and non fatal) | 0.52 [0.09 2.99] | p=1.00 | 0 | 1545 | 2 | REVERSAL,SAGE, | | Coronary event | no data | | Coronary death and non fatal MI | 0.76 [0.45 1.29] | p=1.00 | 0 | 1545 | 2 | REVERSAL,SAGE, | | Coronary death | 0.33 [0.07 1.66] | p=1.00 | 0 | 891 | 1 | SAGE, | | cardiac death | no data | | MACE | 0.72 [0.46 1.13] | p=1.00 | 0 | 891 | 1 | SAGE, | | Non fatal MI | 0.94 [0.47 1.88] | p=1.00 | 0 | 891 | 1 | SAGE, | | All cause death | 0.33 [0.13 0.85] | p=0.04 | 0 | 891 | 1 | SAGE, | | non cardiovascular death | 0.33 [0.07 1.66] | p=1.00 | 0 | 891 | 1 | SAGE, | | Fatal stroke | no data | | Haemmorhagic stroke | no data | | new-onset diabetes | no data | | Death from cancer | 0.20 [0.01 4.17] | p=1.00 | 0 | 891 | 1 | SAGE, | | Rhabdomyolysis | 1.00 [0.06 16.00] | p=1.00 | 0 | 1545 | 2 | REVERSAL,SAGE, | | Myopathy | 1.00 [0.06 16.00] | p=1.00 | 0 | 1545 | 2 | REVERSAL,SAGE, | | Cancer | no data | | Adverse events | 1.01 [0.71 1.44] | p=1.00 | 0 | 1545 | 2 | REVERSAL,SAGE, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| atorvastatin high dose vs simvastatin | No demonstrated result Myopathy by 802% (harmful effect) Adverse events by 130% (harmful effect) suggested Non fatal MI by 17% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Venous thromboembolism | no data | | cardiovascular events | no data | | Cardiovascular death | no data | | stroke (fatal and non fatal) | 0.87 [0.70 1.09] | p=1.00 | 0 | 8888 | 1 | IDEAL, | | Coronary event | 0.89 [0.77 1.02] | p=1.00 | 0 | 8888 | 1 | IDEAL, | | Coronary death and non fatal MI | 0.89 [0.77 1.02] | p=1.00 | 0 | 8888 | 1 | IDEAL, | | Coronary death | 0.99 [0.80 1.22] | p=1.00 | 0 | 8888 | 1 | IDEAL, | | cardiac death | no data | | MACE | no data | | Non fatal MI | 0.83 [0.70 0.99] | p=0.04 | 0 | 8888 | 1 | IDEAL, | | All cause death | 0.98 [0.84 1.14] | p=1.00 | 0 | 8888 | 1 | IDEAL, | | non cardiovascular death | no data | | Fatal stroke | no data | | Haemmorhagic stroke | no data | | new-onset diabetes | no data | | Death from cancer | 0.89 [0.67 1.16] | p=1.00 | 0 | 8888 | 1 | IDEAL, | | Rhabdomyolysis | 0.67 [0.11 4.00] | p=1.00 | 0 | 8888 | 1 | IDEAL, | | Myopathy | 9.02 [2.09 38.90] | p=0.04 | 0 | 8888 | 1 | IDEAL, | | Cancer | no data | | Adverse events | 2.30 [1.92 2.74] | p=0.04 | 0 | 8888 | 1 | IDEAL, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
